Octozi vs QuantHealth (2026)
Two applications of models to clinical development that sit on opposite sides of the moment a protocol is locked. QuantHealth simulates the trial before it runs, letting a team test thousands of protocol variations against modelled populations, which targets the most expensive failure in drug development: a study that could never have worked, discovered after three years and a great deal of money. Octozi works after the design is fixed, automating the data cleaning, reconciliation, review and reporting that determines whether a submission arrives on time, with a published controlled study behind it. They are sequential rather than alternatives. The question to press QuantHealth on is validation: ask how simulated outcomes compared with trials that subsequently ran, because a simulation that makes a marginal protocol look viable is worse than no simulation at all.
- It simulates trial outcomes before a trial runs, letting a development team test thousands of protocol variations against modelled patient populations rather than committing to one design and discovering the problem later.
- Simulation addresses the most expensive failure in drug development, which is a protocol that could not have worked, and it does so while the design is still cheap to change.
- For a sponsor deciding between arms, endpoints and inclusion criteria, the modelling is aimed at the decision rather than at the execution.
- It works the execution layer, cleaning, reconciling, reviewing and reporting trial data, which is where timelines slip after the protocol is fixed.
- The architecture pairs language models with deterministic clinical algorithms, and human in the loop is stated as an architectural commitment rather than a disclaimer.
- A published controlled study with named reviewers reports throughput results, which is unusual evidence for a company at this stage.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Octozi and QuantHealth are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Octozi | QuantHealth |
|---|---|---|
| Primary category | Clinical Trials AI | Clinical Trials AI |
| Founded | 2024 | 2020 |
| Headquarters | New York, New York, United States | Tel Aviv, Israel |
| Website | octozi.com | quanthealth.ai |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Octozi its top capability grade on AI Centrality and Autonomy and Oversight Model. Set against QuantHealth, Octozi grades higher on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards QuantHealth its top capability grade on AI Centrality. Set against Octozi, QuantHealth grades higher on Setting and Specialty Coverage. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Octozi or QuantHealth?
On the axes where the AI Health Index separates them, Octozi grades higher on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure, and QuantHealth grades higher on Setting and Specialty Coverage. Octozi leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Octozi and QuantHealth differ most?
The widest separation the AI Health Index records between Octozi and QuantHealth is on Autonomy and Oversight Model, where Octozi grades A and QuantHealth grades B. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Octozi and QuantHealth grade the same?
The AI Health Index grades Octozi and QuantHealth the same on several axes, including AI Centrality, Clinical and Operational Evidence and Security Certifications and Trust Center. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Trials AI page.
These are sequential rather than competing, one before the protocol is locked and the other after, so a sponsor may use both in the same programme. Simulation carries an exposure worth naming: a modelled trial outcome is only as good as the populations and assumptions behind it, and a simulation that makes a marginal protocol look viable is more dangerous than no simulation at all, so ask what validation exists comparing simulated outcomes to trials that subsequently ran. Neither vendor publishes a security attestation or pricing, and both should be asked whether one sponsor's data informs models serving another.